(WRBY) Warby Parker - Overview
Sector: Healthcare | Industry: Medical Instruments & Supplies | Exchange: NYSE (USA) | Market Cap: 2.995m USD | Total Return: 23.9% in 12m
Avg Turnover: 75.5M
Qual. Beats: 0
Rev. Trend: 99.9%
Qual. Beats: 1
Warnings
Altman Z'' -3.25 < 1.0 - financial distress zone
Volatile Below Avwap Earnings
Tailwinds
No distinct edge detected
Warby Parker Inc. (WRBY) operates as an omnichannel retailer of prescription and non-prescription eyewear, sunglasses, and contact lenses across the United States and Canada. The company integrates its e-commerce platform with a growing physical retail footprint to provide eye exams, vision tests, and optical services. By designing frames in-house and selling directly to consumers, the company bypasses traditional wholesale channels to maintain lower price points than many legacy competitors.
The eyewear industry is characterized by high margins and a shift toward medical-retail integration, where physical storefronts serve as critical hubs for professional eye care services that drive hardware sales. Warby Parker’s business model leverages this by combining its digital Home Try-On program with in-person clinical services to capture a larger share of the patient lifecycle.
Investors can evaluate the long-term sustainability of this growth strategy by reviewing the detailed financial metrics available on ValueRay.
Headquartered in New York and incorporated in 2009, the firm also sells a variety of optical accessories, including anti-fog sprays, travel cases, and sun clip-ons. As a participant in the Other Specialty Retail sub-industry, WRBY competes through a vertically integrated supply chain and a lifestyle-oriented brand identity.
- Brick-and-mortar store expansion drives long-term revenue growth and customer acquisition
- Managed care partnerships increase insurance-covered sales and market share penetration
- Holistic vision care transition through eye exam services boosts average revenue per customer
- Contact lens segment growth improves recurring revenue but pressures overall gross margins
- Marketing spend efficiency and customer acquisition costs impact path to sustainable profitability
| Net Income: 1.35m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.05 > 0.02 and ΔFCF/TA -0.93 > 1.0 |
| NWC/Revenue: 22.95% < 20% (prev 26.16%; Δ -3.21% < -1%) |
| CFO/TA 0.14 > 3% & CFO 105.9m > Net Income 1.35m |
| Net Debt (-50.6m) to EBITDA (45.7m): -1.11 < 3 |
| Current Ratio: 2.33 > 1.5 & < 3 |
| Outstanding Shares: last quarter (125.6m) vs 12m ago 0.74% < -2% |
| Gross Margin: 53.41% > 18% (prev 0.55%; Δ 5.29k% > 0.5%) |
| Asset Turnover: 125.5% > 50% (prev 116.5%; Δ 9.05% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBITDA TTM and Interest Expense TTM) |
| A: 0.28 (Total Current Assets 357.7m - Total Current Liabilities 153.3m) / Total Assets 736.4m |
| B: -0.93 (Retained Earnings -682.4m / Total Assets 736.4m) |
| C: -0.01 (EBIT TTM -6.14m / Avg Total Assets 709.6m) |
| D: -1.90 (Book Value of Equity -684.2m / Total Liabilities 360.6m) |
| Altman-Z'' = -3.25 = D |
| DSRI: 1.07 (Receivables 1.76m/1.47m, Revenue 890.6m/795.1m) |
| GMI: 1.03 (GM 53.41% / 54.79%) |
| AQI: 1.37 (AQ_t 0.02 / AQ_t-1 0.01) |
| SGI: 1.12 (Revenue 890.6m / 795.1m) |
| TATA: -0.14 (NI 1.35m - CFO 105.9m) / TA 736.4m) |
| Beneish M = -2.79 (Cap -4..+1) = A |
As of May 27, 2026, the stock is trading at USD 25.51 with a total of 2,808,833 shares traded.
Over the past week, the price has changed by -10.96%,
over one month by +9.72%,
over three months by -0.55% and
over the past year by +23.90%.
Warby Parker has received a consensus analysts rating of 4.00. Therefore, it is recommended to buy WRBY.
- StrongBuy: 6
- Buy: 3
- Hold: 6
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 29.9 | 17.3% |
P/E Trailing = 2440.5002
P/E Forward = 53.1915
P/S = 3.3629
P/B = 7.9839
Revenue TTM = 890.6m USD
EBIT TTM = -6.14m USD
EBITDA TTM = 45.7m USD
Long Term Debt = 205.8m USD (estimated: total debt 237.6m - short term 31.9m)
Short Term Debt = 31.9m USD (from shortTermDebt, last quarter)
Debt = 237.6m USD (from shortLongTermDebtTotal, last quarter) (leases 237.6m already included)
Net Debt = -50.6m USD (calculated: Debt 237.6m - CCE 288.2m)
Enterprise Value = 2.94b USD (2.99b + Debt 237.6m - CCE 288.2m)
Interest Coverage Ratio = unknown (Ebit TTM -6.14m / Interest Expense TTM 0.0)
EV/FCF = 75.68x (Enterprise Value 2.94b / FCF TTM 38.9m)
FCF Yield = 1.32% (FCF TTM 38.9m / Enterprise Value 2.94b)
FCF Margin = 4.37% (FCF TTM 38.9m / Revenue TTM 890.6m)
Net Margin = 0.15% (Net Income TTM 1.35m / Revenue TTM 890.6m)
Gross Margin = 53.41% ((Revenue TTM 890.6m - Cost of Revenue TTM 414.9m) / Revenue TTM)
Gross Margin QoQ = 54.05% (prev 52.39%)
Tobins Q-Ratio = 4.00 (Enterprise Value 2.94b / Total Assets 736.4m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 237.6m)
Taxrate = 20.54% (821k / 4.00m)
NOPAT = -4.88m (EBIT -6.14m * (1 - 20.54%)) [loss with tax shield]
Current Ratio = 2.33 (Total Current Assets 357.7m / Total Current Liabilities 153.3m)
Debt / Equity = 0.63 (Debt 237.6m / totalStockholderEquity, last quarter 375.8m)
Debt / EBITDA = -1.11 (Net Debt -50.6m / EBITDA 45.7m)
Debt / FCF = -1.30 (Net Debt -50.6m / FCF TTM 38.9m)
Total Stockholder Equity = 368.7m (last 4 quarters mean from totalStockholderEquity)
RoA = 0.19% (Net Income 1.35m / Total Assets 736.4m)
RoE = 0.13% (Net Income TTM 1.35m / Total Stockholder Equity 1.05b)
RoCE = -0.49% (EBIT -6.14m / Capital Employed (Equity 1.05b + L.T.Debt 205.8m))
RoIC = -1.49% (negative operating profit) (NOPAT -4.88m / Invested Capital 326.8m)
WACC = 10.58% (E(2.99b)/V(3.23b) * Re(11.42%) + D(237.6m)/V(3.23b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 11.42% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 86.67 | Cagr: 2.58%
[DCF] Terminal Value 66.59% ; FCFF base≈40.3m ; Y1≈37.7m ; Y5≈34.5m
[DCF] Fair Price = 4.19 (EV 397.7m - Net Debt -50.6m = Equity 448.4m / Shares 107.1m; r=10.58% [WACC]; 5y FCF grow -8.31% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.07 | # QB: 0
Revenue Correlation: 99.90 | Revenue CAGR: 13.66% | SUE: 1.59 | # QB: 1
EPS current Quarter (2026-06-30): EPS=0.12 | Chg30d=-12.50% | Revisions=-43% | Analysts=10
EPS next Quarter (2026-09-30): EPS=0.15 | Chg30d=-2.63% | Revisions=-40% | Analysts=10
EPS current Year (2026-12-31): EPS=0.48 | Chg30d=-1.89% | Revisions=-33% | GrowthEPS=+126.5% | GrowthRev=+12.4%
EPS next Year (2027-12-31): EPS=0.67 | Chg30d=-0.27% | Revisions=-23% | GrowthEPS=+39.8% | GrowthRev=+16.3%
[Analyst] Revisions Ratio: -43%